Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
CGM integration (sensor-augmented pumps) Assign Z79.85 (long-term use of injectable non-insulin antidiabetic drugs) for GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and dual GIP/GLP-1 agonists (tirzepatide)
B12, iron, and magnesium: targeted add-ons B12 Drops 500mcg: Studies have linked low levels of vitamin B12 to low energy and fatigue
Pros of GLP-1s: Non-surgical option Can lead to 1520% body weight loss in clinical trials May improve blood sugar, cholesterol, and inflammation Weekly injections, often self-administered Cons of GLP-1s: Real-world weight loss may be lower than clinical trials (510%) Side effects include nausea, vomiting, fatigue, and gastroparesis High cost and limited insurance coverage Weight may return if medication is stopped What is weight loss surgery
Retatrutide adds two additional mechanisms while producing superior metabolic results
In the STEP 8 trial, more people stopped liraglutide due to side effects (12.6%) than semaglutide (3.2%)
:format(webp))
US$ 24.92
US$ 22.14
US$ 24.94
US$ 21.94
US$ 29.07
US$ 29.48
US$ 20.91
US$ 23.98
US$ 27.25
US$ 20.66
US$ 26.99
US$ 27.30
